Johnson & Johnson (JNJ) News Today

Johnson & Johnson (NYSE: JNJ) shares moved higher today as investors reacted to a string of upbeat analyst actions, a key FDA approval expansion and an upcoming investor presentation, offset in part by a large talc-related jury award.

• Positive Sentiment: Goldman Sachs raised its price target on JNJ from $186 to $212 and maintained a “buy” rating, implying about 11% upside. The Goldman Sachs Group Forecasts Strong Price Appreciation for Johnson & Johnson (NYSE:JNJ) Stock
• Positive Sentiment: Weiss Ratings upgraded JNJ shares from “hold (C+)” to “buy (B–)”. Johnson & Johnson (NYSE:JNJ) Upgraded to Buy (B-) at Weiss Ratings
• Positive Sentiment: Sanford C. Bernstein boosted its JNJ price target to $193. Sanford C. Bernstein Boosts Johnson & Johnson (NYSE:JNJ) Price Target to $193.00
• Positive Sentiment: Citigroup reaffirmed its “buy” recommendation on JNJ. Citigroup Maintains Johnson & Johnson (JNJ) Buy Recommendation
• Positive Sentiment: Johnson & Johnson will present at the UBS Global Healthcare Conference on Nov. 11, including a live webcast of its Fireside Chat. Johnson & Johnson to Participate in the UBS Global Healthcare Conference
• Positive Sentiment: The FDA expanded approval of J&J’s Simponi to pediatric ulcerative colitis patients, based on positive Phase 3 trial data. FDA Expands Johnson & Johnson Ulcerative Colitis Drug Approval To Pediatric Patients
• Positive Sentiment: Analysts at Goldman Sachs reiterated that J&J should outperform in Q3 thanks to strong execution in its Innovative Medicines segment. Goldman Sachs expects another quarter of outperformance from J&J in Q3
• Neutral Sentiment: Zacks published key metrics to watch before J&J’s Q3 earnings release. Wall Street's Insights Into Key Metrics Ahead of Johnson & Johnson (JNJ) Q3 Earnings
• Neutral Sentiment: Zacks highlighted facts to know about J&J as a trending stock. Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Yahoo Finance assessed J&J’s valuation after its recent share price gains. Johnson & Johnson (JNJ): Evaluating Valuation Following Recent Share Price Gains
• Neutral Sentiment: A court vacated a $20 million patent infringement verdict in an orthopedic device case against J&J. Court vacates $20M Johnson & Johnson ortho device patent infringement verdict
• Neutral Sentiment: Bank of America Securities maintained a hold rating on J&J, citing stable revenue and a slight EPS decline. Balanced Outlook for Johnson & Johnson: Hold Rating Amid Stable Revenue and Slight EPS Decline
• Neutral Sentiment: Zacks examined why J&J is poised to beat earnings estimates again, given its history of upside surprises. Why Johnson & Johnson (JNJ) is Poised to Beat Earnings Estimates Again
• Negative Sentiment: A Los Angeles jury ordered J&J to pay $966 million in a talc-related cancer verdict. Johnson & Johnson ordered to pay $966 million in talc cancer case
• Negative Sentiment: The same $966 million talc award was also reported by other outlets, underlining ongoing legal headwinds. J&J hit with $966M jury award in Los Angeles over talc-related cancer case